Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion its initial public offering in the United States. The Somerville, ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate Biomedicines has completed its IPO, raising an impressive $400 million that makes it the largest listing for a biotech on the Nasdaq so far this year. Incubated by investment group Flagship ...

Getting the most out of A/B and other controlled tests by Ron Kohavi and Stefan Thomke In 2012 a Microsoft employee working on Bing had an idea about changing the way the search engine displayed ad ...

Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial ...

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an initial public offering (IPO) in Hong Kong, raising HKD 2.28 billion (around $293 million). The US and Hong ...